Zentalis Pharmaceuticals Inc
ZNTL
NASDAQ
Biotechnology
$3.56
USD
-0.59 (-14.22%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $316.55M
Volume 4.6M
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-139.54M
TTM
+14.3%
YoY
Operating Cash Flow
$-128.09M
TTM
+15.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | -100.0% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 8.4 | 10.8 | 7.9 | 9.1 | 9.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 36.1 | 33.7 | 37.4 | 37.9 | 44.4 |
Operating Income | -36.1 | -33.7 | -37.4 | -37.9 | -44.4 |
EBITDA | -35.9 | -33.6 | -37.2 | -37.7 | -44.2 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 9.2 | 7.0 | 2.6 | 2.6 | 2.2 |
Income Before Income Taxes | -26.9 | -26.7 | -34.8 | -35.2 | -42.1 |
Income Taxes | 0.0 | 0.0 | 0.4 | 0.1 | 0.1 |
Net Income | -26.9 | -26.7 | -35.2 | -35.4 | -42.3 |
Consolidated Net Income / Loss | -26.9 | -26.7 | -35.2 | -35.4 | -42.3 |
Net Income Attributable to Common Shareholders | -26.9 | -26.7 | -35.2 | -35.4 | -42.3 |
Basic EPS | -$0.37 | -$0.37 | -$0.49 | -$0.50 | -$0.59 |
Diluted EPS | -$0.37 | -$0.37 | -$0.49 | -$0.50 | -$0.59 |
Basic Shares Outstanding | 72.0M | 72.1M | 71.7M | 70.3M | 71.3M |
Diluted Shares Outstanding | 72.0M | 72.1M | 71.7M | 70.3M | 71.3M |